Kinetic Biomarker CA-125: Predicting Surgical Success, Survival and Chemosensitivity скачать в хорошем качестве

Kinetic Biomarker CA-125: Predicting Surgical Success, Survival and Chemosensitivity

In a 2024 study involving two Chinese medical centers, a standardized KELIM score of ≥0.925 was identified as an independent predictor for achieving complete cytoreduction (no visible tumor remaining) during interval surgery. Clinical Success Rates: Patients with favorable KELIM scores (≥0.925) were over five times more likely to achieve complete tumor removal compared to those with lower scores. Survival Outcomes: The validation showed significant differences in long-term outcomes based on the score: Progression-Free Survival (PFS): 22.1 months (high score) vs. 15.4 months (low score). Overall Survival (OS): 57.1 months (high score) vs. 42.8 months (low score). Contemporary Treatments: A 2025/2026 study from Dalian and Jiaxing hospitals confirmed KELIM remains a powerful predictor even when using modern therapies like bevacizumab and PARP inhibitors. The research confirms that KELIM is not just a mathematical curiosity but a reliable tool for Chinese clinicians to: -Identify "Poor Responders": Patients with low scores may need more aggressive or innovative drug strategies early on. -Guide Surgery Decisions: It helps determine if a patient is ready for a successful interval debulking surgery (IDS) or if the tumor is still too resistant. -Predict Resistance: It accurately flags patients at high risk for platinum-resistant recurrence, allowing for earlier shifts in treatment plans.